InMed Announces Changes to its Board of Directors
August 09 2022 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the research, development,
manufacturing and commercialization of rare cannabinoids, is
pleased to announce the appointment of Nicole Lemerond to its Board
of Directors, effective immediately.
Nicole Lemerond is a financial executive with
over 25 years of experience in investment management, private
equity, investment banking and leveraged finance. She has
significant experience executing complex transactions, managing
diligence processes, raising capital and structuring balance
sheets. Throughout her career, Ms. Lemerond has worked with
public and private company management teams and boards to increase
stakeholder value. She established and led healthcare groups
at leading investment firms and has also worked at several large
financial institutions, including Lehman Brothers and The Carlyle
Group. Ms. Lemerond holds a Bachelor of Science degree from
Cornell University and is a CFA charterholder.
Contemporaneous with Ms. Lemerond’s appointment,
Adam Cutler has decided to transition off the Board of Directors.
Mr. Cutler has served on the Board since 2015, during which
time his financial and healthcare expertise has been instrumental
in advancing the strategic initiatives of the Company. Over the
years, Mr. Cutler has served as Chair of the Audit
Committee as well as a member Governance and Nomination Committee.
Ms. Lemerond will replace Mr. Cutler as a member of the Audit
Committee and as a member of the Governance and Nomination
Committee.
William Garner, MD, InMed’s Chairman of the
Board of Directors, commented: “I am delighted to welcome Ms.
Lemerond to the Board of Directors at InMed. Nicole joins us with
tremendous financial and healthcare experience and will prove to be
an invaluable asset to the Company. Additionally, on behalf of the
Company, I would like to extend our sincere appreciation to Mr.
Cutler for his significant contributions over the last 6+ years.
His dedication and extensive expertise have been crucial in the
strategic development of InMed and we wish him the best with his
future endeavors.”
About InMed: InMed
Pharmaceuticals is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is also a clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancyVice President,
Investor Relations & Corporate CommunicationsT:
+1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: being a global leader in the research,
development, manufacturing and development of rare cannabinoids;
and delivering new treatment alternatives to patients that may
benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous assumptions
regarding, among other things: the ability to obtain all necessary
regulatory approvals on a timely basis, or at all; and continued
economic and market stability. While InMed considers these
assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and
social uncertainties and contingencies. Additionally, there are
known and unknown risk factors which could cause InMed's actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking information contained herein. A
complete discussion of the risks and uncertainties facing InMed’s
stand-alone business is disclosed in InMed’s Annual Report on Form
10-K and other filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024